Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.78 |
| ▸ | GPX4 | P36969 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8315964 | 0.89 | HDAC6 (0.65) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL8252701 | 0.88 | HDAC6 (1.00) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL8315949 | 0.85 | HDAC6 (0.61) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL8324393 | 0.83 | HDAC6 (0.59) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL28476139 | 0.81 | HDAC6 (0.82) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL8320157 | 0.80 | HDAC6 (0.74) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL29608419 | 0.80 | HDAC6 (0.84) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL28479486 | 0.80 | HDAC6 (0.84) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL28470427 | 0.80 | HDAC6 (0.84) | HDAC6HDAC1GPX4TAAR1TRPV1 | |
| SCHEMBL13627286 | 0.80 | HDAC6 (0.76) | HDAC6HDAC1GPX4TAAR1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235012-A1 | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1633751-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235012-A1 | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors | HDAC1, HDAC7, HDAC2 | HDAC6 11/4885HDAC1 1/4885GPX4 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.